| |
|
|
|
Xtalks, Online
2024-10-15
Chronic liver disease is complex. The causes are multifactorial, disease progression is slow and heterogeneous, and the pathophysiology is complicated and still not entirely understood. This has made drug development challenging, and there are still no approved treatments targeting cirrhosis.
Currently, treatment options are limited to addressing the complications of cirrhosis. But there is a lot of ongoing research activity and exciting progress being made in the field of chronic liver disease.
Join our expert speakers as they walk through the complexity of chronic liver disease and the resulting cirrhosis. This webinar will unpack the drivers of liver disease and its progression via inflammation and fibrosis, as well as the implications for drug development and patient selection. It will also cover some of the biomarkers and other tools, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) alone and in combination with other biomarkers, that can help further our disease understanding and provide valuable insights within drug development.
Join this webinar to learn about chronic liver disease biology and pathophysiology, drug development in this space, and to hear our speakers discuss their perspectives of the future for treatment of chronic liver diseases.
Keywords: Drug Development, Cirrhosis, Liver, Clinical Research, Liver Disease, Biomarkers, NASH, NAFLD, Therapeutic Areas, Fatty Liver, Non-Alcoholic Fatty Liver Disease, MASH
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Quentin Anstee, Dean of Research & Innovation, Professor of Experimental Hepatology, Newcastle University
Lars Johansson, Chief Scientific Officer, Antaros Medical
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-10-15
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|